Datopotamab deruxtecan, DOCETAXEL
D763QC00001
Phase 3 small_molecule active
Quick answer
Datopotamab deruxtecan, DOCETAXEL for TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active